Synopsis: The share of this company jumped 6 percent after a ‘Buy’ rating, driven by attractive valuations, strong outlook, 21 percent upside potential, and a sharp volume surge of nearly 394 percent. The shares of this company, which is one of India’s largest...
Synopsis: The share of this company surged after Nykaa outlined a FY30 vision targeting revenue growth to Rs 43,000 crore, driven by strong Beauty, Fashion, and B2B expansion plans. The share of this company, which is a leading Indian omnichannel e-commerce retailer...
Synopsis: Five undervalued stocks across key sectors with strong fundamentals and brokerage BUY calls, offering up to 70 percent upside driven by earnings growth and supportive industry tailwinds. The Indian equity market continues to offer selective opportunities...
Synopsis: The share of this company gained attention after Citi maintained Buy with 29 percent upside, citing strong demand, emerging businesses growth and steady margin expansion outlook. The article outlines Citi’s rationale behind the upside on this company, which...
Synopsis: Six large-cap companies reported strong Q4 FY26 results with revenue growth up to 312 percent and profit growth up to 426 percent, driven by demand and margin expansion. Large-cap companies often represent stable businesses with strong balance sheets and...
Synopsis: Five stocks where DIIs increased holdings reaching up to 50 percent stake, indicating strong institutional accumulation across turnaround, consumption, healthcare, fintech, and industrial sectors. Domestic Institutional Investors (DIIs) have been steadily...
Synopsis: Several stocks hit 20 percent upper circuit in today’s trade, reflecting strong buying interest, sharp momentum, and active participation across small and mid-cap counters in the broader market. A total of 10 stocks surged to the 20 percent upper circuit in...
Synopsis: Promoter and promoter group entities acquired over 66.6 lakh shares worth approximately Rs 32.18 crore across four companies, reflecting increased promoter holdings and ownership stakes. Promoter transactions remained in focus after several companies...
Synopsis: The share of this company is in focus as the rising chronic mix to 40 percent and BSV-led specialty growth strengthen its 27.1 percent EBITDA margin profile and support long-term profitability. The article outlines how shifting focus strengthens the position...
Synopsis: This company is scaling its US business through product launches, regulatory approvals, and a strong pipeline, aiming to reach USD 1 billion in revenue driven by respiratory and specialty segment expansion. The article outlines the target and capacity of the...
